“My Skin Changed Overnight”

News
Poll

This 66-year-old black woman presented with a 2-year history of a painless skin eruption. She stated that her skin had “changed overnight” while she was caring for her mother who had been hospitalized. Your diagnosis?

This 66-year-old black woman presented with a 2-year history of a painless skin eruption. She stated that her skin had “changed overnight” while she was caring for her mother who had been hospitalized.

Your diagnosis?

A. Livedo reticularis
C. Port-wine stain
B. Cutis marmorata
D. Erythema ab igne
E. Poikiloderma
Related Content
Dupilumab Cardiometabolic Safety in Real-World Study Supports Clinical Trial Evidence / image credit University of Lubeck, Germany

Dupilumab Cardiometabolic Safety in Real-World Study of Atopic Dermatitis Supports Clinical Trial Evidence

Grace Halsey
February 21st 2025
Article

Treatment of AD with dupilumab, compared with cyclosporine and methotrexate, was associated with significantly reduced risk of a wide range of CV outcomes at 1 year.

FDA Clears IND for Alphyn’s Zabalafin Hydrogel for Atopic Dermatitis

FDA Clears IND for Alphyn’s Zabalafin Hydrogel for Atopic Dermatitis

Patient Care Editorial Staff
February 20th 2025
Article

The clearance enables Alphyn to initiate global phase 2b clinical trials, which are anticipated to begin in the first quarter of 2025.

FDA Grants Fast Track Designation to Rezpegaldesleukin for Atopic Dermatitis / Image credit: ©InfiniteStudio/AdobeStock

FDA Grants Fast Track Designation to Rezpegaldesleukin for Atopic Dermatitis

Sydney Jennings
February 10th 2025
Article

Rezpegaldesleukin targets the IL-2 receptor complex to stimulate regulatory T cells, aiming to restore immune balance in people with atopic dermatitis.

Atopic Dermatitis First, Now Onto Asthma for Enveda's Oral Small Molecule Anti-inflammatory Candidate

Atopic Dermatitis First, Now Onto Asthma for Enveda's Oral Small Molecule Anti-inflammatory Candidate

Grace Halsey
February 7th 2025
Article

The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.

Dupilumab Drug Survival Rates Superior to Those for Upadacitinib and Tralokinumab in Atopic Dermatitis: Large-Scale, Real-World Data

Dupilumab Drug Survival Rates Superior to Those for Upadacitinib and Tralokinumab in Atopic Dermatitis: Large-Scale, Real-World Data

Grace Halsey
February 7th 2025
Article

A first large-scale comparison of length of treatment with advanced AD therapies also identified reasons for discontinuation and examined prior use of biologics and JAK inhibitors.

Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use / image Eric Simpson, MD, MRC, Oregon Health & Science University

Atopic Dermatitis Update: Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use

Grace Halsey
February 5th 2025
Article

Improvement in AD signs and symptoms continued through 56 weeks of treatment with the PDE4 inhibitor including when used just twice weekly as prophylaxis.

© 2025 MJH Life Sciences

All rights reserved.